Macchia E, Fenzi G F, Monzani F, Bartalena L, Lippi F, Aloisio V, Cupini C, Baschieri L, Pinchera A
J Endocrinol Invest. 1983 Oct;6(5):375-8. doi: 10.1007/BF03347619.
Inhibition of binding of TSH to thyroid plasma membranes by immunoglobulins G (IgG) from patients with Graves' disease has been interpreted as evidence of an interaction with the TSH receptor, but other explanations may account for this phenomenon. Displacement of receptor-bound TSH might be a more direct index of such an interaction. The aim of the present study was to assess TSH-displacing activity (TDA) of Graves' IgG by a newly developed assay and compare TDA to TSH-binding inhibiting activity (TBIA) and thyroid-stimulating antibody (TSAb) activity. TDA was assessed by preincubating 125I-TSH with thyroid plasma membranes and by measuring residual bound 125I-TSH after addition of IgG. TBIA was evaluated by determining binding of 125I-TSH to thyroid plasma membranes preincubated with IgG. Results were expressed as % TSH-displacing or binding inhibition activities of test IgG with respect to normal control IgG. The percent of TDA positive Graves' IgG preparations (72.7%) was greater than that of TBIA positive (48.5%). There was no correlation between TDA and TBIA results, since 11 Graves' IgG preparations were TDA positive but TBIA negative, and 6 were TDA negative but TBIA positive. Hashimoto's or idiopathic myxedema IgG preparations were positive in 2/7 in the TDA and in 1/7 in the TBIA assays, respectively. Neither TDA nor TBIA correlated with TSAb determined by cAMP accumulation in thyroid plasma membrane. The TDA assay developed in this study appeared to be more sensitive than the more widely used TBIA assay.(ABSTRACT TRUNCATED AT 250 WORDS)
来自格雷夫斯病患者的免疫球蛋白G(IgG)对促甲状腺激素(TSH)与甲状腺质膜结合的抑制作用,已被解释为与TSH受体相互作用的证据,但其他解释也可能说明这一现象。受体结合型TSH的置换可能是这种相互作用更直接的指标。本研究的目的是通过一种新开发的检测方法评估格雷夫斯病IgG的TSH置换活性(TDA),并将TDA与TSH结合抑制活性(TBIA)和促甲状腺素抗体(TSAb)活性进行比较。通过将125I-TSH与甲状腺质膜预孵育,并在加入IgG后测量残留的结合型125I-TSH来评估TDA。通过测定125I-TSH与预先用IgG孵育的甲状腺质膜的结合来评估TBIA。结果以测试IgG相对于正常对照IgG的TSH置换或结合抑制活性百分比表示。TDA阳性的格雷夫斯病IgG制剂百分比(72.7%)高于TBIA阳性的百分比(48.5%)。TDA和TBIA结果之间没有相关性,因为11份格雷夫斯病IgG制剂TDA阳性但TBIA阴性,6份TDA阴性但TBIA阳性。桥本氏病或特发性黏液水肿的IgG制剂在TDA检测中分别为2/7阳性,在TBIA检测中为1/7阳性。TDA和TBIA均与通过甲状腺质膜中cAMP积累测定的TSAb无关。本研究中开发的TDA检测方法似乎比使用更广泛的TBIA检测方法更敏感。(摘要截于250字)